Bill
AB 259
AB 259 would cap Nevada drug reimbursements at the federal Medicare maximum fair price during the price period, enforcing civil penalties for overcharges.
AB 259 would have required that purchases and reimbursements for certain prescription drugs dispensed, delivered or administered in Nevada not exceed the federal Medicare “maximum fair price” (MFP) for those drugs during the applicable federal price period. The bill was intended to limit state drug spending and address high prescription drug costs by using the Medicare negotiated price as a statewide price cap.
Stakeholders (pharmacy associations, wholesalers, industry groups, patient and provider organizations) raised concerns in testimony and letters:
- Risk that reimbursement caps below acquisition cost could force providers or pharmacies to stop stocking or administering medicines, harming access (especially specialty, pediatric cancer, rural and safety‑net providers).
- Possible negative effects on 340B, Medicaid Drug Rebate program flows, and provider revenues that support patient services.
- Administrative and enforcement costs for the state and potential market disruption through conflicts with national supply‑chain pricing (wholesale contracts often priced nationally/out‑of‑state).
- Constitutional and federal preemption issues were flagged (Commerce Clause, Supremacy Clause, Takings/Due Process), and industry argued MFP was designed for Medicare markets, not as a universal benchmark.
- Critics also noted that MFP caps may not reduce patients’ out‑of‑pocket costs because patient cost shares are determined by plan design and PBMs.
This summary captures the bill’s core mechanics, intended effect, principal exemptions, enforcement framework, stakeholder concerns, and procedural outcome (veto).
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
